Sanofi India Limited - Asset Resilience Ratio
Sanofi India Limited (SANOFI) has an Asset Resilience Ratio of 1.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SANOFI current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Sanofi India Limited's Asset Resilience Ratio has changed over time. See SANOFI total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sanofi India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SANOFI market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs148.00 Million | 1.18% |
| Total Liquid Assets | Rs148.00 Million | 1.18% |
Asset Resilience Insights
- Limited Liquidity: Sanofi India Limited maintains only 1.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sanofi India Limited Industry Peers by Asset Resilience Ratio
Compare Sanofi India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.03% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
Annual Asset Resilience Ratio for Sanofi India Limited (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Sanofi India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.18% | Rs148.00 Million ≈ $1.60 Million |
Rs12.55 Billion ≈ $135.70 Million |
-17.41pp |
| 2024-12-31 | 18.59% | Rs3.00 Billion ≈ $32.41 Million |
Rs16.12 Billion ≈ $174.31 Million |
-0.98pp |
| 2023-12-31 | 19.57% | Rs3.36 Billion ≈ $36.29 Million |
Rs17.15 Billion ≈ $185.45 Million |
-28.03pp |
| 2022-12-31 | 47.60% | Rs9.86 Billion ≈ $106.64 Million |
Rs20.72 Billion ≈ $224.05 Million |
+47.20pp |
| 2021-12-31 | 0.40% | Rs123.00 Million ≈ $1.33 Million |
Rs30.61 Billion ≈ $331.04 Million |
-0.56pp |
| 2020-12-31 | 0.96% | Rs281.00 Million ≈ $3.04 Million |
Rs29.18 Billion ≈ $315.62 Million |
-31.50pp |
| 2019-12-31 | 32.46% | Rs10.53 Billion ≈ $113.89 Million |
Rs32.44 Billion ≈ $350.87 Million |
+4.58pp |
| 2018-12-31 | 27.88% | Rs8.32 Billion ≈ $89.97 Million |
Rs29.84 Billion ≈ $322.70 Million |
+17.02pp |
| 2017-12-31 | 10.86% | Rs3.02 Billion ≈ $32.62 Million |
Rs27.77 Billion ≈ $300.32 Million |
-9.11pp |
| 2016-12-31 | 19.97% | Rs5.07 Billion ≈ $54.85 Million |
Rs25.40 Billion ≈ $274.69 Million |
+27.18pp |
| 2015-12-31 | -7.21% | Rs-1.73 Billion ≈ $-18.75 Million |
Rs24.05 Billion ≈ $260.05 Million |
-18.33pp |
| 2011-12-31 | 11.12% | Rs1.67 Billion ≈ $18.07 Million |
Rs15.03 Billion ≈ $162.50 Million |
-7.11pp |
| 2010-12-31 | 18.23% | Rs2.57 Billion ≈ $27.77 Million |
Rs14.08 Billion ≈ $152.31 Million |
-- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, S… Read more